NCT07527221 2026-04-14
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
Phase 1 Not yet recruiting
Clinical Trials
13 trialsNCT07341048 2026-01-15
ACTIVAQ
Hospices Civils de Lyon
Phase NA Not yet recruiting
NCT04576156 2025-12-04
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Geron Corporation
Phase 3 Active not recruiting
NCT06421025 2025-11-21
POLYVISCO
Hospices Civils de Lyon
Recruiting
NCT03008642 2025-09-19
Poly-CO
Centre Hospitalier Universitaire, Amiens
Phase NA Completed
NCT05481151 2025-08-13
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
PharmaEssentia
Phase 3 Active not recruiting
NCT06785870 2025-01-21
EVEREST
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not yet recruiting
NCT02218047 2021-06-01
CONTI-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT02252159 2021-04-26
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Incyte Corporation
Completed
NCT01998828 2020-04-20
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Phase 2 Terminated
NCT02523638 2016-02-17
PEN-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT01645124 2012-07-20
CYTO-PV
Consorzio Mario Negri Sud
Phase 3 Terminated
NCT00866762 2011-12-12
A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
Copenhagen University Hospital at Herlev
Phase 2 Unknown